Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shomron Ben-Horin
Bella Ungar

Showing results (1-10 of 343) with videos related to

Pageof 35
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 11, 2016
ReplyShomron Ben-Horin, Bella Ungar
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment durationShomron Ben-Horin, Bella Ungar
Alimentary Pharmacology & Therapeutics|February 28, 2019
Letter: double-dose intensification-a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors replyBella Ungar, Shomron Ben Horin, Xavier Roblin
Journal of Crohn'S & Colitis|January 31, 2016
Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus ErythematosusShomron Ben-Horin, Bella Ungar, Rami Eliakim, et al.
United European Gastroenterology Journal|March 27, 2024
A Gastroenterologist's guide to drug interactions of small molecules for inflammatory bowel diseaseSivan Harnik, Bella Ungar, Ronen Loebstein, et al.
The Israel Medical Association Journal : IMAJ|December 26, 2021
Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?Ido Veisman, Doron Yablecovitch, Uri Kopylov, et al.
Inflammatory Bowel Diseases|August 30, 2020
Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn DiseaseAhmad Albshesh, Bella Ungar, Shomron Ben-Horin, et al.
Case Reports in Gastroenterology|August 11, 2022
Acute Chest Pain as an Infusion Reaction to VedolizumabAsaf Levartovsky, Miri Yavzori, Ella Fudim, et al.
Crohn'S & Colitis 360|February 13, 2023
Incidentally Diagnosed Asymptomatic Crohn's Disease: A Retrospective Cohort Study of Long-Term Clinical OutcomesAna Grinman, Bella Ungar, Adi Lahat, et al.
Annals of Gastroenterology|July 3, 2023
Outcome of inflammatory bowel disease patients with prior malignancyUria Shani, Eyal Klang, Simon Lassman, et al.
Pageof 35

Showing results (1-10 of 343) with videos related to

Sort By:
Pageof 35
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 11, 2016
ReplyShomron Ben-Horin, Bella Ungar
Alimentary Pharmacology & Therapeutics|January 29, 2022
Letter: loss of response to anti-TNFα agents in patients with inflammatory bowel disease depends on treatment durationShomron Ben-Horin, Bella Ungar
Alimentary Pharmacology & Therapeutics|February 28, 2019
Letter: double-dose intensification-a quick way to reverse antibody formation and loss of response in patients treated with adalimumab. Authors replyBella Ungar, Shomron Ben Horin, Xavier Roblin
Journal of Crohn'S & Colitis|January 31, 2016
Infliximab Efficacy and Safety in an Ulcerative Colitis Patient with Systemic Lupus ErythematosusShomron Ben-Horin, Bella Ungar, Rami Eliakim, et al.
United European Gastroenterology Journal|March 27, 2024
A Gastroenterologist's guide to drug interactions of small molecules for inflammatory bowel diseaseSivan Harnik, Bella Ungar, Ronen Loebstein, et al.
The Israel Medical Association Journal : IMAJ|December 26, 2021
Predictors of Immunogenicity to Infliximab among Patients with Inflammatory Bowel Disease: Does Ethnicity Matter?Ido Veisman, Doron Yablecovitch, Uri Kopylov, et al.
Inflammatory Bowel Diseases|August 30, 2020
Terminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn DiseaseAhmad Albshesh, Bella Ungar, Shomron Ben-Horin, et al.
Case Reports in Gastroenterology|August 11, 2022
Acute Chest Pain as an Infusion Reaction to VedolizumabAsaf Levartovsky, Miri Yavzori, Ella Fudim, et al.
Crohn'S & Colitis 360|February 13, 2023
Incidentally Diagnosed Asymptomatic Crohn's Disease: A Retrospective Cohort Study of Long-Term Clinical OutcomesAna Grinman, Bella Ungar, Adi Lahat, et al.
Annals of Gastroenterology|July 3, 2023
Outcome of inflammatory bowel disease patients with prior malignancyUria Shani, Eyal Klang, Simon Lassman, et al.
Pageof 35